Mastitis Market Segmentation by Treatment (Antibiotics, and Others); by End User (Hospitals, Academic Institutes, Hospital & Clinics, and Others); and by Type (Clinical, and Sub-Clinical Intramammary Inflammation)-Global Demand Analysis & Opportunity Outlook 2031
Product Code: RP-ID-10078505 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10078505
Market Overview:
Mastitis Market Segmentation by Treatment (Antibiotics, and Others); by End User (Hospitals, Academic Institutes, Hospital & Clinics, and Others); and by Type (Clinical, and Sub-Clinical Intramammary Inflammation)-Global Demand Analysis & Opportunity Outlook 2031
Global Mastitis Market Highlights Over 2022- 2031
The global mastitis market is estimated to grow at a ~5% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of approximately USD 2.0 billion in 2021. The growth of the market can be attributed to the rising cases of mastitis that are expected to affect the growth of the countries’ GDP through a reduction in milk production, the degradation milk quality, and others. As per the International Dairy Foods Association, the dairy industry contributes 3.5 percent of the U.S. GDP. Furthermore, the increase in the number of cattle herds and the rise in the fertility rate are also anticipated to surge the growth of the global mastitis market.
GET A SAMPLE COPY OF THIS REPORT
The global mastitis market is segmented by type into clinical, and sub-clinical intramammary inflammation. Out of these, the clinical intramammary inflammation segment is anticipated to hold the largest share over the forecast period owing to the increase in the number of cases of clinical intramammary inflammation in dairy cattle and the growing number of dairy animals.
Global Mastitis Market Regional Synopsis
Regionally, the global mastitis market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the Asia Pacific region is estimated to witness modest growth over the forecast period on the back of the rise in the pregnancy rates and an increase in the cattle population. According to the United Nations Children’s Fund, every day approximately 67,385 babies are born in India, which accounts for one-sixth of the worldwide child births. Moreover, the rise in the number of mastitis cases and the number of people suffering from chronic diseases is anticipated to surge the growth of the mastitis market in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global mastitis market includes the following segments:
By Treatment
-
Antibiotics
-
Vaccines
-
Others
By End User
-
Hospitals
-
Academic Institutes
-
Hospital & Clinics
-
Others
By Type
-
Clinical
-
Sub-Clinical Intramammary Inflammation
Growth Drivers and Challenges Impacting the Growth of the Global Mastitis Market
Growth Drivers
-
Rising cases of mastitis that are expected to affect the growth of the countries’ GDP
-
Increase in the number of cattle herds
Challenges
-
Lack of knowledge among the people related to mastitis
-
Lack of resources with farmers for the treatment of their cattle
Key Companies Dominating the Global Mastitis Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global mastitis market that are included in our report are Bayer AG, Pfizer Inc., Elanco, Ceva, Boehringer Ingelheim International GmbH., Sanofi, Novartis AG, Merck & Co., Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, and others.
Latest Developments in the Global Mastitis Market:
-
15 April 2021: Ingelheim Boehringer Ingelheim GmbH., announced that its Ubroseal internal teat sealant was upgraded to Ubroseal Blue. As part of the Company's mastitis portfolio, Ubroseal Blue will be available in selected countries worldwide.
-
19 July 2019: Sure Petcare (Merck & Co., Inc.,) announced the release of the SureFeed Microchip Pet Feeder Connect, the next generation of the best-selling SureFeed Microchip Pet Feeder, which monitors pets' eating habits. The smart feeder tracks how much and when a pet eats and sends real-time updates to the owner's phone.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the client's requirements helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Bayer AG
- Pfizer Inc.
- Elanco
- Ceva
- Boehringer Ingelheim International GmbH.
- Sanofi
- Novartis AG
- Merck & Co.Inc.
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd
Related Reports
Study Period : 2023-2035
Report Format : PDF,PPT
Delivery Timeline : 48-72 Business Hours
Proof of Quality & Reliability
